Cochlear (FRA:OC5) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OC5 Cochlear Ltd FRA:OC5
72 GF Score
Price €73.46
GF Value €187.96
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Cochlear FFO?

FFO (Funds from operations) only applies to REITs.

FRA:OC5
72GF Score
Cochlear Ltd FRA:OC5
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cochlear (FRA:OC5) Overvalued in 2026?

Based on GuruFocus' analysis, Cochlear stock appears to be undervalued. The current stock price of €73.46 is trading 60.9% below its estimated GF Value™ of €187.96. GuruFocus considers Cochlear to be Significantly Undervalued.

Key valuation signals for FRA:OC5:

  • FFO:
  • GF Value™: €187.96 vs. price of €73.46 (60.9% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the FRA:OC5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cochlear Business Description

Address 1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
72GF Score

Get the complete analysis for FRA:OC5

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.46
Price
€187.96
GF Value